FDA announces approval of at-home brain therapy for adults with major depressive disorder, suggesting a new treatment option for those unresponsive to antidepressants.
The Food and Drug Administration (FDA) on Jan. 12 announced its approval of the first prescription, physician‐directed, at‐home brain neuromodulation therapy as an adjunctive treatment for adults with major depressive disorder (MDD) who failed to achieve satisfactory improvement from at least one previous antidepressant.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: